fbpx

Nyheder

Lundbeckfonden Ventures nyheder

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces a...
Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support commercial activities This announcement contains inside information for the purposes of Article 7...
Former Celgene Business Development Head Brings Entrepreneurial Expertise and Life Science Business Leadership CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board...
Lund, Sweden, 12:00 pm CET, 30 December 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votestoday announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgerytoday...
Lund, Sweden, 15:00 CET, 18 December 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team. Kristina Ingvar starts with the company February 1, 2020 and will formally take on the position as the Executive Vice President Quality Management & Regulatory Affairs of the company...
Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgery. The authors concluded that CERAMENT® BVF was as good as autograft with regard to both...
November 25, 2019 at 8:49 AM CET Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis As announced in Company Release no. 18/2019, Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the...
November 25, 2019 at 8:29 AM CET Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the ”Offeror”) have today entered into a transaction agreement (the ”Transaction Agreement”) pursuant to which...
Lund, Sweden, 16:00 CET, November 12 2019 – BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019. Fergus MacLeod starts in the position as the company´s General Manager & Executive Vice President Commercial Operations EUROW. Fergus MacLeod has more...
1 2 3 4 63

Lundbeckfonden Ventures

Nyheder

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
17. februar 2020
Spero Therapeutics Announces Commencement of Rights Offering
11. februar 2020
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
5. februar 2020